Aim: The aim of this study was to evaluate the effect of Kava-241, an optimized Piper methysticum Kava compound, on periodontal destruction in a collagen antibody primed oral gavage model of periodontitis. 
| INTRODUCTION
Periodontitis is a chronic inflammatory disease with a high prevalence, with over 47% of the US adult population is affected (Eke, Dye, Wei, Thornton-Evans, & Genco, 2012) . Bacteria from supra-and subgingival biofilms are considered key aetiological factors (Hajishengallis & Lamont, 2012) . Among them, Porphyromonas gingivalis (P. gingivalis) is a well-documented pathogen recognized as a predominant contributor to periodontitis (Hajishengallis, 2009) able to induce disease in established animal models that have demonstrated similarities to human pathology (Graves, Fine, Yen-Tung, Van Dyke, & Hajishengallis, 2008; Graves, Kang, Andriankaja, Wada, & Rossa, 2012) . Recognition of bacterial surface antigens by Toll-like receptors (TLRs), TLR2 and TLR4 specifically, induces secretion of a wide range of proinflammatory cytokines such as interleukin-1β (IL-1β), IL-6, IL-11, IL-17, and tumour necrosis factor-alpha (TNF-α) from resident or recruited inflammatory cells (Taylor, 2010) . This sustained inflammation is also associated to the recruitment and activation of osteoclasts through the secretion of receptor activator of nuclear factor κB ligand (RANKL) contributing to alveolar bone destruction (Lapérine et al, 2016 ) and periodontitis worsening.
Several studies demonstrated a bidirectional link between periodontitis and arthritis, which led to the development of investigational murine models mainly based on type II collagen antibody injection (AB) (Tang & Amar, 2016) . Interestingly, some have proposed an impact of type II collagen injections on alveolar bone loss (Corrêa et al, 2017) . However, none have evaluated the impact of AB priming on the periodontal destruction initiated by
P. gingivalis.
Non-surgical therapy is considered the gold standard of periodontal treatment. It consists of oral hygiene instruction and scaling and root planing aiming at disturbing bacterial biofilms. Despite good results and improvement in clinical parameters, some systemic or local risk factors may impair treatment response (Bouchard, Carra, Boillot, Mora, & Rangé, 2016) . For example, some susceptible sites, such as deep pockets or furcations of multirooted teeth, remain difficult to treat and may require surgical intervention (Heitz-Mayfield & Lang, 2013) . To improve non-surgical treatment outcomes and to reduce the need of surgery, several additive therapies have been developed such as the use of antiseptics, antibiotics, probiotics, or anti-inflammatory drugs (Agossa, Morand, Tenenbaum, Davideau, & Huck, 2016; Martin-Cabezas, Davideau, Tenenbaum, & Huck., 2016; Mombelli, Cionca, & Almaghlouth, 2011) . However, neither are definitive in halting periodontitis and some are associated with serious side effects or poor patient compliance. Thus, there is a need to develop novel pharmaceutical alternatives of synthetic or natural origins with improved success rate for periodontal therapy (Alani & Seymour, 2014) .
Kava, a compound extracted from the Piper methysticum plant, has been suggested to be responsible for the low incidence of cancer in natives of Polynesia and Micronesia (Singh, 1992) . It has been credited for its relaxing, sedative, anxiolytic, antiarthritic and antiinflammatory properties (Shimoda, Park, Stokes, Halenani Gomes, & Turner, 2012; Teschke & Lebot, 2011) . Kava mainly constitutes of kavalactones and, in smaller amounts, flavokavain (Folmer et al, 2006) .
Recently, it was demonstrated that kavain-derived compounds are able to inhibit TNF-α secretion in vitro and in vivo through ERK/ LITAF-related pathway modulation (Pollastri et al, 2009; Tang & Amar, 2016) . In its natural state, kava extract has been reported to cause adverse effects including hepatic, neurologic, and dermatological toxicity (Gounder, 2006) . Therefore, research has focused on identification of active compounds with low risk of toxicity (Pollastri et al, 2009) , high solubility and stability in vivo, and a high rate of cell permeability. We reported recently the moderate but beneficial effect of kava on a conventional oral gavage model of periodontitis (Yuan, Gupte, Zelkha, & Amar, 2011) . In the light of these findings, the present aimed at evaluating the impact of AB injection on periodontal destruction associated to P. gingivalis gavage and, secondarily, to test whether Kava-241 is effective in prevention or treatment of advanced periodontal inflammation and related alveolar bone destruction.
| MATERIALS AND METHODS

| Kava-241 compound
Our objective in medicinal chemistry and biochemical screening efforts was to optimize the structure of the natural product kavain known for its potential anti-inflammatory properties. Our effort generated a kava analogue with optimized activity. The synthesis of the unsaturated enone of the Kavain analogue is illustrated in Figure 1 
Clinical Relevance
Scientific rationale for study: There are currently no definitive therapeutic approaches for treatment of periodontitis. We sought to demonstrate the efficacy of a novel antiinflammatory agent in the treatment of periodontitis in a murine model. 
| Bacterial culture
The W83 P. gingivalis strain was used to induce periodontitis (BAA-308; ATCC). This pathogen was cultured and maintained in Schaedler anaerobe broth (Oxoid Ltd., Basingstoke, Hampshire, UK), supplemented with hemin (5 μg/ml; Sigma-Aldrich, St. Louis, MO, USA), menadione (1 μg/ml; Sigma-Aldrich), and sodium bicarbonate (420 μg/ml; Sigma-Aldrich) in an anaerobic chamber with 85% N 2 , 10% H 2 , and 5% CO 2 at 37°C.
| TNF-α ELISA
The supernatants from treated cells were subjected to ELISA for the detection of TNF-α concentration with an Invitrogen kit (KMC3011; ThermoFisher, Dublin, OH, USA). ELISA immunoreactivity was quantified using a microplate reader (Bio-Rad, Hercules, CA, USA).
| Cytotoxicity assay
Cell viability was measured using a Cell Counting Kit-8 (CCK-8) (Sigma-Aldrich). Briefly, cells were treated with Kava-241 (300 μg/ml) for 4 hr. CCK-8 was then added into the cell's medium for an incubation time of 2 hr, and absorbance was calculated at 450 nm to determine the number of viable cells.
| Animals, experimental periodontitis, and treatment procedures
Forty-nine-six-week-old, pathogen-free DBA1/BO male mice (Taconic Farm, Rensselaer, NY, USA) were used in this study.
Mice were fed sterile food and distilled water ad libitum. All procedures were approved by local ethical committee. Experimental periodontitis was induced by delivery of 5 × 10 8 CFU P. gingivalis through oral gavage as described previously (Yuan et al, 2013) during 15 days. Mice were randomly assigned to one of seven groups ( Figure 2 ): a P. gingivalis-infected and AB-injected group; a P. gingivalis-infected group, AB-injected and Kava-241 treatment group; a P. gingivalis-infected, AB-injected and Kava-241 prevention group; a P. gingivalis-infected only group; AB only group; Kava-241 treatment only group; and a Kava-241 preventive only group.
Mice were given sulfamethoxazole at 0.87 mg/ml and trimethoprim at 0.17 mg/ml ADD (Hi-Tech Pharmacal Co. Inc., Armityville, NY, USA) in milli-Q water ad libitum for 10 days, followed by 3 days without antibiotics. Mice in the P. gingivalis-infected group were anaesthetized with isoflurane and were inoculated with an average 5 × 10 8 CFU of P. gingivalis in 100 μl of phosphate-buffered saline with 2% carboxymethylcellulose (Sigma-Aldrich) administered by oral gavage for 15 days (1 inoculation/day). The non-P. gingivalisinfected group was inoculated with 2% carboxymethylcellulose only (Sigma-Aldrich). Mice in the P. gingivalis + AB group were injected intraperitoneally with ArthritoMab (CIA-MAB-2C, MD Bioproducts) on day 1 (7 mg/mouse) and day 5 (4 mg/mouse). Mice in the Kava-241 treatment group were intraperitoneally injected with 40 mg/kg of the Kava-241 on days 5, 8, 11, and 14 of the experiment. Mice in the Kava-241 prevention groups were intraperitoneally injected with two doses (40 mg/kg) of Kava-241. In this group, the first dose was administered 3 and 1 days before the P. gingivalis oral gavage administration followed by injection at 2, 6, 9, and 13 days. Left side of mice skulls was mechanically defleshed after 15 min of treatment in boiling water, washed with PBS, and then exposed overnight in 3% hydrogen peroxide. Then, they were washed with PBS three times for 5 min, immersed in bleach for 1 min, washed again with PBS three times for 5 min, and then dried at 37°C for 1 hr. Skulls were stained at room temperature with 1% methylene blue (Sigma-Aldrich)
for 1 min and dried for 30 min at 37°C.
| Histomorphometric and morphometric analysis
Palatal root and furcation of first and second molars were consid- 
| Inflammatory cell histomorphometric analysis
A minimum of six fields from each inter-dental area (from CEJ to root apex of the second molar) were analysed. Analysis was performed only for sections where the root canal systems of the adjacent teeth were visible and properly oriented. In each area of interest, the total number of inflammatory cells (polymorphonuclear neutrophils [PMN] , mononuclear leucocytes, and fibroblasts) was counted manually from images captured at 400× magnification on HE-stained sections as described previously (Yuan et al, 2011) . The data were then reported as the number of each type of cell per μm 2 .
| Statistical analysis
All measurements were performed blinded and double-checked at a one-week interval. Intra-examiner variation was found to be <5%.
All values were expressed as mean ± SEM. An ANOVA (one-way) followed by Tukey's post hoc analysis was performed for multiple comparison. A p-value <.05 was considered to be statistically significant.
All in vitro experiments have been performed at least in triplicate.
| RESULTS
| In vitro evaluation of Kava-241 antiinflammatory properties and cytotoxicity
The cytotoxic and anti-inflammatory effects of kava and Kava-241
were evaluated. Cell viability and LPS-induced TNF-α secretion of RAW cells exposed to either kava, Kava-241 or left untreated have been measured. Kava-241 and kava reduced significantly LPS-induced TNF-α secretion (85% and 72%, respectively) after 1 hr (Figure 3a) relative to untreated cells. The anti-TNF-α effect obtained by Kava-241 was significantly greater than the one obtained with kava parent molecule (p < .05), while the same trend was observed after 4 hr of treatment. Regarding cytotoxicity, Kava-241 treatment was associated to reduced cell death than kava treatment (p < .05; Figure 3b ).
These results emphasized the safe usage of Kava-241 as a potential therapeutics.
| Periodontal destruction associated to P. gingivalis is increased by collagen-AB injection
In 
| Effect of Kava-241 treatment on epithelial down-growth and alveolar bone loss
To evaluate the therapeutic effect of Kava-241, the P. gingivalis + AB model was selected as it displays more severe periodontal destruction and allows more efficient evaluation of potential therapeutic effects of a drug. Both Kava-241 approaches, either treatment or prevention, significantly reduced epithelial down-growth. 
| Effect of treatments on inflammatory cell infiltrate
Epithelial down-growth (a) and alveolar bone loss (b). Epithelial down-growth was defined by measuring the distance from the cemento-enamel junction (CEJ) to the apical extent of the junctional epithelium. Alveolar bone loss was measured as the distance between the CEJ and the alveolar bone crest (ABC). Results are expressed in μm (*p < .05 versus Porphyromonas gingivalis +AB; +p < .05 versus P. gingivalis)
Morphometric analysis of alveolar bone loss. Representatives of the alveolar bone loss in each group. Images were captured at 3.5× after methylene blue staining Kava-241 treatment group and 27.47% in preventive treatment group).
| DISCUSSION
This study demonstrated the relevance of a new model of experimental periodontitis occurring in a shorter period of time (10-14 days) while producing advanced periodontal bone loss and the potential therapeutic effects of a kavain-derived compound, Kava-241, used as a treatment or in a preventive manner. To induce epithelial downgrowth and alveolar bone loss, several models of experimental periodontitis can be used including oral gavage or use of infected ligatures that can display differential trend of tissular destruction (Graves et al, 2012) . The oral gavage model is a well-described model of experimental periodontitis. Here, an optimized oral P. gingivalis gavage model, primed by AB injections, was used to evaluate the Kava-241 therapeutic effect on induced epithelial down-growth, alveolar bone loss and inflammatory cells recruitment.
Herein, the injections of AB concomitant to administration of P. gingivalis through oral gavage synergistically increased the epithelial down-growth and alveolar bone loss in comparison with P. gingivalis oral gavage alone. This approach induced periodontal lesions in a shorter period of time compared with P. gingivalis gavage alone.
The magnitude of the periodontal destruction allowed a significant effect size amenable for the evaluation of novel anti-inflammatory therapeutics with minimal risk of complications such as increased period of disease induction or increased risk of mouse death that may occur in case of surgical approach or repeated anaesthesia. AB is a well-described method to induce arthritis in mice (Sim, Lee, Lee, & Kang, 2016; Tang & Amar, 2016) . Rheumatoid arthritis and periodontitis shared several aetiopathogenic mechanisms related to the immune host response and to cytokines secretion (Culshaw, McInnes, & Liew, 2011) . Recently, in a rat model of experimental periodontitis, the bidirectional interaction between these diseases was illustrated by an increase in alveolar bone loss in rats affected by both periodontitis and arthritis induced by type II collagen injection (Corrêa et al, 2017) . Underlying mechanisms explaining the increase in periodontal . A minimum of six fields from each inter-dental area (from CEJ to root apex of the second molar) were analysed, and cells were counted manually from images captured at 400× magnification on H and E-stained sections destruction are still unknown; however, recent reports suggested arthritis-related cytokines IL-1, TNF-α, or IL-17 known for their role in OPG/RANKL expression and bone homeostasis (Chen et al, 2014; Takahashi et al, 2014) as potential contributor also to periodontal tissue destruction (Corrêa et al, 2017) . Therefore, this new model of periodontitis induction may be useful to evaluate drug effect on severe form of murine periodontitis.
Several therapeutic agents targeting key inflammatory markers such as COX-2 and TNF-α have already been proposed to treat periodontitis and to promote regeneration of periodontium such as NSAIDs or omega-3 fatty acid (Kesavalu et al, 2007; Morand et al, 2016) . However, none is considered to be a key element of the periodontal treatment. In this study, we evaluated the impact of a specific kava-derived compound on periodontal destruction induced by P. gingivalis. has been selected to be tested in vivo based on its in vitro properties. Indeed, we showed that Kava-241 had a significantly less cell cytotoxic effect than kava, a possible reason behind hepatotoxicity (Martin, Johnston, Xing, & Hegeman, 2014; Olsen, Grillo, & Skonberg, 2011) . These properties may promote the use of in the safe management of periodontal diseases. Furthermore, Kava-241 cell treatment reduced more efficiently LPS-induced TNF-α than parent kava, making it a good candidate as a therapeutic agent and clearly optimizing its effect compared to parent kava. Antimicrobial properties of kava have also been proposed; however, our in vitro evaluation did not show significant effect of Kava-241 on P. gingivalis growth (data not shown).
In vivo, Kava-241 treatment resulted in a reduction of periodontal breakdown, inflammatory cell infiltrate, and increased the number of fibroblasts. These observations are consistent with findings of our prior study where parent kava compound was tested in an experimental periodontitis mouse model and was shown to reduce inflammatory infiltrate measured by PMN and mononuclear cells counts and increased fibroblasts (Yuan et al, 2011) . Regarding the specific effects of Kava-241 on the cell count, our hypothesis was that the Kava-241 would also reduce the inflammation and promote wound healing resulting in an increase in connective tissues. Indeed, Kava-241 promoted greater reduction in periodontal inflammation (decrease of PMN, leucocytes, key mediators of inflammation and immune response) and improved significantly parameters of wound healing (i.e. fibroblast counts) than parent kava compound. However, further experimentation is required to determine the cell-specific effects of Kava-241.
To date, only a small number of studies have evaluated the potential therapeutic interest of kavain or related compounds in the context of infectious or inflammatory diseases (World Health Organization 2007) . Therefore, the precise mechanisms activated or inhibited by kava are not very well described. However, some recent data suggest that kavain or other derived molecules, such as flavokavains, act on molecular pathways that are activated by lipopolysaccharide (LPS) such as NF-kB, AP-1, and ERK (Kwon, Ju, Yoon, Choi, & Park, 2013; Tang & Amar, 2016) . In vitro, it was demonstrated in macrophages stimulated by LPS, that flavokavain-A inhibits iNOS and COX-2 expression (Kwon et al, 2013) . iNOS is a free radical associated with the pathogenesis of several inflammatory diseases, and its expression is increased in periodontitis tissues indicating a possible involvement in tissular destruction related to the inflammation (Shaker, Ghallab, Hamdy, & Sayed, 2013) . COX-2 is a key enzyme associated to inflammatory response and to PGE 2 synthesis, a key mediator of hostimmune response associated with periodontitis (Schaefer et al, 2010) .
It has been also demonstrated in a rat model of experimental periodontitis that P. gingivalis induces COX-2 expression emphasizing the role of this pathway in periodontal tissue destruction (Oliveira et al, 2008) .
In another study, kavain was able to inhibit TNF-α secretion induced by LPS (Tang & Amar, 2016) . TNF-α is a hallmark of periodontal inflammation, and its increase has been documented in periodontitis (Özer Yücel et al, 2015) and in response to infection with periodontal pathogens including P. gingivalis and its virulence factors in several cell types (Huck et al, 2017; Kocgozlu, Elkaim, Tenenbaum, & Werner, 2009 ). Interestingly, Folmer et al showed that kava compounds are able to inhibit TNF-α induced NF-kB activation, a key transcription factor involved in immune and inflammatory response (Folmer et al, 2006) . NF-kB activation has been observed in response to periodontal infection, and recognition of P. gingivalis through TLRs and activation of NF-kB is associated to osteoclastogenesis modulation (Zhang et al, 2011) . This pathway, targeted by kava, may explain the decrease in alveolar bone loss observed in our model. In vivo, the anti-inflammatory properties of kava that were measured in an induced inflammatory paw model were its injection reduced from 90% of the swelling induced by E. coli-LPS (Tang & Amar, 2016) , demonstrating the promising antiinflammatory properties of kava.
| CONCLUSION
Our results provide evidence that injection of AB concomitant with P. gingivalis oral gavage aggravates periodontal destruction and may be used as a faster and more reliable disease model. Furthermore, Kava-241 compound could effectively reduce P. gingivalis-associated periodontal destruction, suggesting its use as a promising therapeutic agent of periodontal diseases in the future. However, some future studies should focus on determining the most effective dosing regimen and its full mode of action in comprehensive structure-function experiments, especially regarding the impact of Kava-241 on bone remodelling.
